CS
CTMX icon

Credit Suisse’s CytomX Therapeutics CTMX Stock Holding History

Credit Suisse’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-35
Closed – – 4078
2022
Q2 		$0 Buy
+35
New +$67 ﹤0.01% 3992
2021
Q4 		– Sell
-30,179
Closed -$153K – 4524
2021
Q3 		$153K Sell
30,179
-15,544
-34% -$83.2K ﹤0.01% 4279
2021
Q2 		$289K Buy
45,723
+3,718
+9% +$29K ﹤0.01% 4129
2021
Q1 		$325K Sell
42,005
-66,171
-61% -$524K ﹤0.01% 3972
2020
Q4 		$709K Sell
108,176
-30,411
-22% -$217K ﹤0.01% 3592
2020
Q3 		$921K Sell
138,587
-48,874
-26% -$362K ﹤0.01% 2992
2020
Q2 		$1.56M Buy
187,461
+67,335
+56% +$625K ﹤0.01% 2579
2020
Q1 		$921K Sell
120,126
-5,635
-4% -$39.3K ﹤0.01% 2715
2019
Q4 		$1.04M Buy
125,761
+36,191
+40% +$244K ﹤0.01% 3082
2019
Q3 		$661K Buy
89,570
+53,478
+148% +$528K ﹤0.01% 3271
2019
Q2 		$404K Sell
36,092
-15,300
-30% -$160K ﹤0.01% 3527
2019
Q1 		$553K Buy
51,392
+18,901
+58% +$279K ﹤0.01% 3265
2018
Q4 		$490K Sell
32,491
-5,130
-14% -$76.1K ﹤0.01% 3272
2018
Q3 		$696K Buy
37,621
+321
+0.9% +$7.31K ﹤0.01% 3102
2018
Q2 		$853K Sell
37,300
-10,295
-22% -$263K ﹤0.01% 3125
2018
Q1 		$1.35M Buy
47,595
+14,549
+44% +$415K ﹤0.01% 2742
2017
Q4 		$697K Buy
33,046
+8,524
+35% +$177K ﹤0.01% 3245
2017
Q3 		$445K Buy
+24,522
New +$383K ﹤0.01% 3562
2017
Q1 		– Sell
-12,735
Closed -$139K – 3845
2016
Q4 		$139K Sell
12,735
-5,530
-30% -$67K ﹤0.01% 3895
2016
Q3 		$286K Buy
18,265
+4,388
+32% +$53.1K ﹤0.01% 3675
2016
Q2 		$142K Buy
+13,877
New +$158K ﹤0.01% 3989

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Credit Suisse's CTMX Position: Q3 2022 in Review

Credit Suisse sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 35 shares.

Credit Suisse first reported a position in CTMX in Q2 2016 and held it in 21 quarters. The position peaked at $1.56M in Q2 2020. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • Credit Suisse reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 35 CytomX Therapeutics shares in Q3 2022.
  • Credit Suisse first reported a position in CytomX Therapeutics in Q2 2016 and held it in 21 quarters.
  • Credit Suisse's CytomX Therapeutics position peaked at $1.56M in Q2 2020.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.